MITOBRIDGE
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies, the Company is progressing innovative approaches to the treatment of diseases with a high unmet medical need. Their strategy is to establish proof of concept in rare diseases and then expand into more common diseases. Mitobridge has assembled a strong team with expertise in advancing g... round-breaking therapeutics into the clinic. Their scientific founders and advisors include leaders in mitochondrial biology, metabolism, and aging with experience in translating novel discoveries into next-generation medicines. The Company was founded in October of 2013 with financing from MPM Capital, Longwood Fund, and Astellas Pharma and a shared vision for the promise of mitochondrial-targeted therapeutics.
MITOBRIDGE
Industry:
Biotechnology Life Science Therapeutics
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.mitobridge.com
Total Employee:
11+
Status:
Active
Contact:
(617)401-9100
Email Addresses:
[email protected]
Total Funding:
5.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Font Awesome Apache
Current Employees Featured
Founder
Investors List
MPM Capital
MPM Capital investment in Series A - Mitobridge
Astellas Pharma
Astellas Pharma investment in Series A - Mitobridge
Longwood Fund
Longwood Fund investment in Series A - Mitobridge
MPM Capital
MPM Capital investment in Seed Round - Mitobridge
Official Site Inspections
http://www.mitobridge.com
- Host name: slab500.com
- IP address: 209.68.21.212
- Location: Pittsburgh United States
- Latitude: 40.4236
- Longitude: -79.9825
- Metro Code: 508
- Timezone: America/New_York
- Postal: 15203
More informations about "Mitobridge"
Mitobridge - MitoWorld
Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in …See details»
Mitobridge - Crunchbase Company Profile & Funding
Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Their scientific founders and advisors include leaders in mitochondrial biology, metabolism, and aging with experience in …See details»
Engineered Small Molecules | Astellas Pharma Inc.
ESM team is a new organization established in April 2024 by the merger of TPD and the Mitobridge Division, comprised of Mitobridge, Inc. (now Astellas Engineered Small Molecules US, Inc.) and Nanna Therapeutics Ltd. (now …See details»
Accelerating the discovery and development of novel …
Dec 23, 2020 · Mitobridge strengthens our research and development capabilities in the mitochondrial field, specifically, obtaining the Peroxisome Proliferator-Activated Receptor delta (PPARδ) franchise, a result of a collaboration …See details»
Mitobridge Company Profile 2024: Valuation, Investors …
Developer of small molecule therapeutics designed to enhance mitochondrial function.See details»
Mitobridge, Inc. - MassBio
Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in …See details»
Astellas Completes Acquisition of Mitobridge, Inc. - PR Newswire
Jan 23, 2018 · By exercising the option right to acquire Mitobridge, Astellas paid $225 million1 to acquire 100% of the equity in Mitobridge. In addition, Mitobridge shareholders will be eligible for...See details»
Mitobridge Company Profile - Office Locations, Competitors
Mitobridge is a biotech company developing molecule therapeutics to improve mitochondrial function. It also provides treatment for musculoskeletal, metabolic, and neurodegenerative …See details»
Mitobridge - VentureRadar
Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in …See details»
Mitobridge - Org Chart, Teams, Culture & Jobs | The Org
Mitobridge is a biotechnology company discovering and developing new small molecule modulators that boost mitochondrial functions. It takes less than ten minutes to set up your …See details»
News | Astellas Pharma Inc.
Jan 24, 2018 · At this point, Astellas will maintain the organization in Cambridge, MA, and retain the Mitobridge name as a division of Astellas. Astellas is still reviewing the impact of the …See details»
Mitobridge - Leadership Team - The Org
The Leadership Team at Mitobridge comprises visionary scientists and experienced executives dedicated to driving the company’s mission of enhancing mitochondrial function through …See details»
Astellas Pharma US | Astellas Completes Acquisition of Mitobridge
Jan 23, 2018 · We acquired Mitobridge, Inc. to accelerate R&D in diseases associated with mitochondrial dysfunctions.See details»
Astellas | Biopharmaceutical - Cambridge Chamber of Commerce
Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in …See details»
US company licenses IP from EPFL to develop mitochondria boosters
Feb 10, 2017 · Mitobridge, a US biopharmaceutical company developing drugs that improve mitochondrial function, has licensed intellectual property from the lab of Johan Auwerx at EPFL.See details»
Daniel Hoeppner - Director, Target ID & Business Development
Dr. Hoeppner (Director, Mitobridge) is Head of Target Identification and Business Development. He manages the Exploratory Biology team aimed at populating the early pipeline. Prior to …See details»
Astellas buys DMD drug in $450M mitochondrial takeover
Dec 1, 2017 · Astellas has acquired its partner Mitobridge in a deal worth up to $450 million. The takeover gives Astellas full control of a phase 1 Duchenne muscular dystrophy (DMD) drug in …See details»
News | Astellas Pharma Inc.
Dec 1, 2017 · Under the 2013 partnership agreements, Astellas and Mitobridge have collaborated to discover and develop compounds that target mitochondrial function. These drug candidates …See details»
Investigational DMD Therapy MA-0211 to Be Tested in Healthy...
Aug 11, 2017 · MA-0211, a modulator of peroxisome proliferator-activated receptor (PPAR) delta, was developed under the company’s mitochondrial enhancement platform in collaboration with …See details»
Boston Area Web Design & Digital Marketing | Slabmedia
Professional, custom designed web sites that elevate your brand. Our Boston Web Design company has a mission to create a web-presence that will keep your visitors interested and …See details»